Company Profile
Greenwich LifeSciences Stock Price, News & Analysis
- Ticker:
- GLSI
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
14.24 USD (-1.04%)
Close
Last updated: August 6, 2026
357M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, GLSI closed down 1.04% at $14.24. No new same-company headline was identified in the current news window.
Company overview
Business overview
Greenwich LifeSciences is an immunotherapy company focused on cancer vaccines and breast-cancer treatment. Its story is built around a narrow but potentially differentiated oncology program.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Greenwich sits in specialty oncology biotechnology.
Business Model Characteristics
The company depends on clinical data, target validation, and the possibility of creating a focused cancer-immunotherapy franchise.
Position Within the Biotechnology Landscape
Greenwich is a high-catalyst oncology name whose stock is very sensitive to trial and translational outcomes.
Future catalysts
Greenwich’s catalysts are its breast-cancer immunotherapy program and any update that shows the platform still has a path forward. The next development step matters because the story is still highly data-dependent.
Recent news
- 01
Greenwich LifeSciences Announces Approval to Expand FLAMINGO-01 into the United Kingdom
Source: Greenwich LifeSciences
- 02
Greenwich LifeSciences Provides Clinical Updates on FLAMINGO-01
Source: Greenwich LifeSciences
- 03
Greenwich LifeSciences Announces European Approval for Combining Both HLA Populations in FLAMINGO-01
Source: Greenwich LifeSciences
- 04
Greenwich LifeSciences Announces European Approval for Use of Commercially Manufactured GP2 in FLAMINGO-01
Source: Greenwich LifeSciences
- 05
Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at ASCO Meeting 2026
Source: Greenwich LifeSciences
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Greenwich LifeSciences (GLSI)?
Greenwich LifeSciences (GLSI) most recently closed at 14.24 USD, a -1.04% move versus the previous session.
What is the market cap of Greenwich LifeSciences (GLSI)?
Greenwich LifeSciences currently has a market capitalization of 357M USD on BioPharmSignal.
What does Greenwich LifeSciences do?
Greenwich LifeSciences is an immunotherapy company focused on cancer vaccines and breast-cancer treatment. Its story is built around a narrow but potentially differentiated oncology program.
On which exchange is GLSI stock listed?
Greenwich LifeSciences (GLSI) is associated with NASDAQ, United States, Biopharma.
What is Greenwich?
Greenwich’s catalysts are its breast-cancer immunotherapy program and any update that shows the platform still has a path forward.
Which conditions is Greenwich LifeSciences targeting with Greenwich?
Greenwich LifeSciences is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Greenwich LifeSciences describe recent progress with Greenwich?
Greenwich’s catalysts are its breast-cancer immunotherapy program and any update that shows the platform still has a path forward.
What is LifeSciences?
Greenwich LifeSciences is an immunotherapy company focused on cancer vaccines and breast-cancer treatment.